135 related articles for article (PubMed ID: 25684180)
1. Clinicopathologic Implications of Eukaryotic Initiation Factor 3f and Her-2/neu Expression in Gastric Cancer.
Cheng Y; Zhou J; Li H
Clin Transl Sci; 2015 Aug; 8(4):320-5. PubMed ID: 25684180
[TBL] [Abstract][Full Text] [Related]
2. Decreased expression of eukaryotic initiation factor 3f is an adverse prognostic factor for stage I-III gastric cancer.
Li G; Wang N; Sun C; Li B
World J Surg Oncol; 2014 Mar; 12():72. PubMed ID: 24678890
[TBL] [Abstract][Full Text] [Related]
3. Expression of eukaryotic initiation factor 3f is associated with prognosis in gastric carcinomas.
Cheng Y; Jia C; Li G; Li H
Oncol Res Treat; 2014; 37(4):198-202. PubMed ID: 24732644
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of nucleophosmin/B23 and human epidermal growth factor receptor 2/neu expressions in gastric cancers.
Zhou F; Qiu W; Sun L; Xiang J; Sun X; Sui A; Ding A; Yue L
APMIS; 2013 Jul; 121(7):582-91. PubMed ID: 23489260
[TBL] [Abstract][Full Text] [Related]
5. Significance of TFF3 protein and Her-2/neu status in patients with gastric adenocarcinoma.
Xu CC; Yue L; Wei HJ; Zhao WW; Sui AH; Wang XM; Qiu WS
Pathol Res Pract; 2013 Aug; 209(8):479-85. PubMed ID: 23822993
[TBL] [Abstract][Full Text] [Related]
6. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.
Begnami MD; Fukuda E; Fregnani JH; Nonogaki S; Montagnini AL; da Costa WL; Soares FA
J Clin Oncol; 2011 Aug; 29(22):3030-6. PubMed ID: 21709195
[TBL] [Abstract][Full Text] [Related]
7. HER-2/neu amplification is an independent prognostic factor in gastric cancer.
Park DI; Yun JW; Park JH; Oh SJ; Kim HJ; Cho YK; Sohn CI; Jeon WK; Kim BI; Yoo CH; Son BH; Cho EY; Chae SW; Kim EJ; Sohn JH; Ryu SH; Sepulveda AR
Dig Dis Sci; 2006 Aug; 51(8):1371-9. PubMed ID: 16868827
[TBL] [Abstract][Full Text] [Related]
8. Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival.
He XX; Ding L; Lin Y; Shu M; Wen JM; Xue L
J Clin Pathol; 2015 May; 68(5):374-80. PubMed ID: 25731189
[TBL] [Abstract][Full Text] [Related]
9. HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients.
Liu W; Zhong S; Chen J; Yu Y
J Clin Gastroenterol; 2012 Apr; 46(4):e31-7. PubMed ID: 22064554
[TBL] [Abstract][Full Text] [Related]
10. [Association of HER-2/neu expression with prognosis of gastric cancer].
Chen B; Luo RC; Cui F; Qian XY
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Mar; 26(3):344-7. PubMed ID: 16546744
[TBL] [Abstract][Full Text] [Related]
11. Serum level of HER-2/neu in patients with gastric cancer: correlation with HER-2/neu overexpression in gastric carcinoma tissue.
Kono K; Naganuma H; Sekikawa T; Amemiya H; Takahashi A; Iizuka H; Matsumoto Y
Tumour Biol; 2000; 21(3):139-44. PubMed ID: 10754464
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor receptor 4 protein expression and clinicopathological features in gastric cancer.
Chen H; Shen DP; Zhang ZZ; Liu JH; Shen YY; Ni XZ
World J Gastroenterol; 2015 Feb; 21(6):1838-44. PubMed ID: 25684949
[TBL] [Abstract][Full Text] [Related]
13. Correlations of β-catenin, Ki67 and Her-2/neu with gastric cancer.
Wu HW; Qin CY; Huang JL; Kong XY; Wang WJ; Bai WK
Asian Pac J Trop Med; 2014 Apr; 7(4):257-61. PubMed ID: 24507671
[TBL] [Abstract][Full Text] [Related]
14. HER-2/neu and TOPIIa expression in gastric cancer reflect disease severity.
Liu HQ; Zhang SL; Song S
Hepatogastroenterology; 2012 Jun; 59(116):1290-3. PubMed ID: 22281973
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma.
Khan AJ; King BL; Smith BD; Smith GL; DiGiovanna MP; Carter D; Haffty BG
Clin Cancer Res; 2002 Feb; 8(2):540-8. PubMed ID: 11839675
[TBL] [Abstract][Full Text] [Related]
16. Is Helicobacter Pylori associated with Her2/neu Overexpression in Gastric Cancer Patients who Underwent Curative Resection?
Yoo MW; Han HS; Kim SY; Cho YH; Lee HG; Kim JH; Bang HY; Lee KY; Yoon SY
Hepatogastroenterology; 2014 May; 61(131):858-62. PubMed ID: 26176087
[TBL] [Abstract][Full Text] [Related]
17. Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial.
Zhou F; Li N; Jiang W; Hua Z; Xia L; Wei Q; Wang L
World J Surg Oncol; 2012 Dec; 10():274. PubMed ID: 23249720
[TBL] [Abstract][Full Text] [Related]
18. LAPTM4B-35, a cancer-related gene, is associated with poor prognosis in TNM stages I-III gastric cancer patients.
Cheng X; Zheng Z; Bu Z; Wu X; Zhang L; Xing X; Wang X; Hu Y; Du H; Li L; Li S; Zhou R; Wen XZ; Ji JF
PLoS One; 2015; 10(4):e0121559. PubMed ID: 25849595
[TBL] [Abstract][Full Text] [Related]
19. The prognostic significance of p53, p27 kip1, p21 waf1, HER-2/neu, and Ki67 proteins expression in gastric cancer: a clinicopathological and immunohistochemical study of 121 Arab patients.
Al-Moundhri MS; Nirmala V; Al-Hadabi I; Al-Mawaly K; Burney I; Al-Nabhani M; Thomas V; Ganguly SS; Grant C
J Surg Oncol; 2005 Sep; 91(4):243-52. PubMed ID: 16121348
[TBL] [Abstract][Full Text] [Related]
20. Her-2/neu assessment for gastric carcinoma: validation of scoring system.
Mrklic I; Bendic A; Kunac N; Bezic J; Forempoher G; Durdov MG; Karaman I; Prusac IK; Pisac VP; Vilovic K; Tomic S
Hepatogastroenterology; 2012; 59(113):300-3. PubMed ID: 22260838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]